Capromorelin
(Ghrelin)PreclinicalSmall molecule
Ghrelin is used to stimulate appetite and help people gain weight, particularly in cancer patients who have lost their appetite, and in dogs with poor appetite.[1] Capromorelin is currently being investigated across 4 indications[3], with its most advanced program in Preclinical.[1]
Capromorelin is one of 84 small molecule programs targeting Cystic Fibrosis. It is currently in Preclinical.
4
Indications
20
Total Trials
0
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Avelox
BayerPhase 2
Lamprene
NovartisPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Sirturo
WWim Janssens
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Verapamil Hydrochloride
Mylan Pharmaceuticals IncPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alcohol1 trial
Effects of Ghrelin on Alcohol Cue Reactivity and Craving
Completed·—·N/A·NCT01190085·45 enrolled
12 more indications
Heavy Drinker1 trial
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT01779024·17 enrolled
Cachexia1 trial
Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study
Completed·—·Phase 1/2·NCT00933361·21 enrolled
Endothelial Dysfunction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ghrelin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Aarhus